Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis.
about
Indomethacin treatment slows disease progression and enhances a Th1 response in susceptible BALB/c mice infected with Leishmania majorInterleukin-4 but not gamma interferon production correlates with the severity of murine cutaneous leishmaniasis.Interleukin-7 enhances antimicrobial activity against Leishmania major in murine macrophagesAn avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent L. majorNucleosomal histone proteins of L. donovani: a combination of recombinant H2A, H2B, H3 and H4 proteins were highly immunogenic and offered optimum prophylactic efficacy against Leishmania challenge in hamsters.The meteorology of cytokine storms, and the clinical usefulness of this knowledgeDeficiency in tumor necrosis factor alpha activity does not impair early protective Th1 responses against blood-stage malariaLow-dose UVB contributes to host resistance against Leishmania amazonensis infection in mice through induction of gamma interferon and tumor necrosis factor alpha cytokines.Distinct eosinophil cytokine expression patterns in skin diseases - the possible existence of functionally different eosinophil subpopulations.Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone.17-AAG kills intracellular Leishmania amazonensis while reducing inflammatory responses in infected macrophages.Inhibition of growth of Mycobacterium avium in murine and human mononuclear phagocytes by migration inhibitory factorInduction of tumor necrosis factor alpha by the group- and type-specific polysaccharides from type III group B streptococci.Deficiency of Leishmania phosphoglycans influences the magnitude but does not affect the quality of secondary (memory) anti-Leishmania immunity2,3,7,8-tetrachlorodibenzo-p-dioxin slows the progression of experimental cutaneous Leishmaniasis in susceptible BALB/c and SCID micePatterns of cytokine secretion in murine leishmaniasis: correlation with disease progression or resolutionDefect in the tissue cellular immune response: experimental visceral leishmaniasis in euthymic C57BL/6 ep/ep miceParticipation of lipopolysaccharide-binding protein in lipopolysaccharide-dependent macrophage activation.Human macrophages acquire a hyporesponsive state of tumor necrosis factor alpha production in response to successive Mycobacterium avium serovar 4 stimulationImmune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans.Association of Leishmania heat shock protein 83 antigen and immunoglobulin G4 antibody titers in Brazilian patients with diffuse cutaneous leishmaniasis.Cytokines, Toxoplasma and intracellular parasitism.Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis.Tumor necrosis factor alpha (TNF-alpha) and TNF-beta and their receptors in experimental cutaneous leishmaniasis.Tumor necrosis factor alpha augments nitric oxide-dependent macrophage cytotoxicity against Entamoeba histolytica by enhanced expression of the nitric oxide synthase gene.Transforming growth factor-beta in human cutaneous leishmaniasisBoth the Fas ligand and inducible nitric oxide synthase are needed for control of parasite replication within lesions in mice infected with Leishmania major whereas the contribution of tumor necrosis factor is minimal.Tumor necrosis factor alpha inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor.Specific uptake of tumor necrosis factor-alpha is involved in growth control of Trypanosoma brucei.Enhanced survival of Leishmania major in neutrophil granulocytes in the presence of apoptotic cells.Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in miceT cell and non-T cell compartments can independently determine resistance to Leishmania major.A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice.Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response.Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo.Heterogeneity in lymphokine profiles of CD4+ and CD8+ T cells and clones activated in vivo and in vitro.Lutzomyia longipalpis salivary gland homogenate impairs cytokine production and costimulatory molecule expression on human monocytes and dendritic cells.Tegumentary leishmaniasis in childhood.A protective role for endogenous tumor necrosis factor in Toxoplasma gondii infection
P2860
Q28375573-9C7E9C85-BE1F-4EE2-A82C-F3B259E7A080Q33605647-4B2F308E-23CD-4768-9DBC-5554DD2C09E3Q33609250-3F0ADDED-142D-4881-9AAD-AA912A74BA52Q33617127-8D1AD9DC-04DD-467A-85F8-99136CAB6AD4Q33753259-999FE9F7-747E-4384-B4AF-5EF0FE2B0D90Q33867213-414ACD57-60FA-4B3E-8280-7A3A64844479Q33868104-66C0C8E2-3879-4BBA-B4B4-452E248CE39FQ33943048-1764234F-CE7E-4885-96D6-F901E97963DDQ34007831-794A8F7F-06CD-4CAB-A62C-12C5D5856F39Q34381322-982355BB-9295-4C12-8470-FCB16250FA35Q34478035-B8FE01FC-9C78-4CEA-8D32-DE25EB81BD00Q34522402-1A2FE0C7-BF54-43D3-A1FA-2C53F8292F0EQ34529051-599236CE-70F8-4EC8-BFFF-4A41512E4FF6Q34776215-05CA1328-96EE-4B1E-8427-FCC977993081Q35009314-EA8D9FD5-88D4-409F-AF0E-30ACD0460B7FQ35108546-C61C932F-E372-4E5D-B97F-F547795465FBQ35108659-AAD5CDB9-8EFE-4793-ACC2-6EE7887D0BCBQ35335499-8560A309-4888-4409-A5A5-61E044E68989Q35411519-8B5D55AE-592A-423E-9B5B-7857A39F8CBCQ35445608-02D0009D-E798-4230-A6D3-13D90D35D3D8Q35561363-18E3DB97-4E75-4D0A-AF03-188D165272E5Q35732488-428B3843-6B7B-44F0-B984-F31A62E7C21CQ35774776-6C3E291B-76E0-4E18-BA83-1E216AC19F7BQ35777068-2E7E73C6-53C9-4139-9C99-97C872C60AA7Q35778238-7BDFB712-9530-4A2B-9531-31E8FC237887Q35798613-77C5C43B-1A69-451F-B629-4E552F6C28D8Q35801828-C40C7AF5-18C2-425B-9916-E8D8909B83CEQ35871524-0C331EBA-661E-42C9-9076-896D65EB004CQ36274117-3CF5E497-DD2C-48D5-8AB4-545EE2C66288Q36276999-5CB068F8-BA17-4EFD-BF2F-F0F114FAD578Q36362141-74A36E80-07DB-4F2A-A52B-58202B6AC67EQ36364627-469DE7E4-F571-45F7-8410-A37EC15B5582Q36364671-C1F1FB81-5526-4B9F-A124-4BC0A9BCC2FEQ36374716-548690F5-9928-4520-A880-94EEF410AB07Q36377246-18838389-FB55-4562-A6BF-00B1E170E3DFQ36539199-9E45BDA8-34A8-4DD2-9A39-533E6507ED05Q36539242-8CFE5140-E010-45B5-A1D3-B86C2FA2EA66Q36576090-05534694-ADAB-46DD-B32C-D68068CCEC9EQ36841009-D3999EC4-AC17-4992-89DA-D8D966AE2BD5Q36945212-F73D7FFA-F078-4F33-BBED-899CDE06B1B2
P2860
Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Tumor necrosis factor plays a ...... urine cutaneous leishmaniasis.
@ast
Tumor necrosis factor plays a ...... urine cutaneous leishmaniasis.
@en
type
label
Tumor necrosis factor plays a ...... urine cutaneous leishmaniasis.
@ast
Tumor necrosis factor plays a ...... urine cutaneous leishmaniasis.
@en
prefLabel
Tumor necrosis factor plays a ...... urine cutaneous leishmaniasis.
@ast
Tumor necrosis factor plays a ...... urine cutaneous leishmaniasis.
@en
P2093
P2860
P356
P1476
Tumor necrosis factor plays a ...... urine cutaneous leishmaniasis.
@en
P2093
P2860
P304
P356
10.1084/JEM.170.6.2097
P407
P577
1989-12-01T00:00:00Z